Compare Inovio Pharmaceuticals Inc (INO) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Thomson Reuters Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M), while Thomson Reuters Corp trades at $103.31 (market cap $43.89B). The key difference: Thomson Reuters Corp is far larger — about 391.2× Inovio Pharmaceuticals Inc's market cap, and Thomson Reuters Corp pays a 2.58% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Thomson Reuters Corp for 63 Days on average.
| INO | TRI | |
|---|---|---|
Market Cap | $112.19M | $43.89B |
Volume | 3,201,278 | 1,648,199 |
Sector | Health | Industrials |
52-Week High | $2.65 | $163.45 |
52-Week Low | $0.66 | $76.55 |
Typical Hold Time | 43 Days | 63 Days |
Enterprise Value | $83.51M | $46.51B |
Dividend Yield | — | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
Thomson Reuters (TRI) trades at $101.71, up 2.45% today, with a bullish technical outlook and strong analyst consensus. The stock shows robust fundamentals with a 21.22% net income margin and 10% organic growth in core businesses. Recent strategic moves include divesting its print unit to focus on technology and launching a proprietary AI model, positioning for future growth.
The outlook is positive with a consensus price target of $133.25, implying significant upside. Key risks include execution of the AI strategy and cybersecurity concerns. Institutional buying and insider purchases support confidence, but investors should monitor earnings performance and competitive pressures in the legal tech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
